In February 2025, a six-month-old baby named KJ received a personalized CRISPR therapy for a rare genetic liver condition at Children's Hospital of Philadelphia. More than a year later, he is alive. His case made the cover of TIME magazine and stands as proof that individualized gene editing can work inside a single patient.
What it cannot prove is whether anyone can afford to do it again.
The FDA issued draft guidance on February 23, 2026 outlining when individualized genetic therapies could proceed under a simplified regulatory pathway called the Plausible Mechanism Framework. The guidance described conditions under which early clinical evidence from one patient might substitute for the full Phase 1 safety battery required of mass-market drugs. The idea was genuinely good news for a field that had spent years fighting manufacturing requirements designed for drugs made in factories, not hospitals.
The exemption from current good manufacturing practice, or cGMP, regulations covers studies designed to establish basic safety. It does not clearly cover studies intended as primary effectiveness evidence. One attorney at Ropes & Gray described the distinction in a March 2026 alert: the exemption generally applies to studies designed to establish basic safety, rather than efficacy of the drug product. You can run the experiment. You cannot approve the drug.
The gap matters because individualized CRISPR therapies face a structural problem: a single-patient trial is, by necessity, the primary evidence of whether the therapy works. There is no Phase 3 to fall back on. The Plausible Mechanism Framework addresses what happens before a patient receives a therapy. It says nothing about the infrastructure required to manufacture and distribute that therapy at commercial scale.
The clearest evidence that the gap is not theoretical: EveryONE Medicines, the first company explicitly formed to commercialize individualized genetic therapies, shut down in March 2026. The company was founded by Julia Vitarello, who trained in Jennifer Doudna's lab at UC Berkeley, and was built around the premise that the FDA framework would eventually make personalized medicine commercially viable. It raised money, assembled a team, and concluded that the math still did not work.
The science moved forward. The economics did not follow.
What academic teams can do, and have done, is demonstrate that the biology works. The CHOP and Penn researchers who treated Baby KJ for CPS1 deficiency achieved results significant enough to warrant publication and public recognition. Kiran Musunuru and Rebecca Ahrens-Nicklas, the two physicians who led the work, were named to the TIME 100 Health list this year. Baby KJ was treated at between six and seven months of age and survived. The team has since presented preclinical data on a two-part prime editing platform showing 30 to 40 percent correction rates in liver DNA across animal models of urea cycle disorders, a family of seven related genetic conditions that share a biological pathway.
The question the Plausible Mechanism Framework was supposed to answer was whether a single-patient result could substitute for a conventional trial. The answer, increasingly, is yes for the experiment and no for the approval.
The CHOP and Penn team is now proposing an umbrella trial that would enroll patients across all seven urea cycle disorder genes under a single investigational new drug application. One researcher has said academic groups pursuing this path will need industry partners to meet approval standards, which is a precise way of saying that university laboratories can generate the evidence and not much else.
The financial problem is separate from the regulatory one. exa-cel, the first approved CRISPR therapy for sickle cell disease and beta-thalassemia, carries a list price of $2.2 million per patient. That number reflects development costs, manufacturing complexity, and the small patient populations that cannot spread overhead across high volumes. EveryONE Medicines concluded that no amount of regulatory flexibility changes the underlying calculus: individualized therapies for ultra-rare diseases require factory-scale investment for patient-scale returns.
